Top > Search of International Patents > PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES

PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES meetings

Foreign code F170009151
File No. S2015-1886-C0
Posted date Aug 16, 2017
Country WIPO
International application number 2016JP071224
International publication number WO 2017018288
Date of international filing Jul 20, 2016
Date of international publication Feb 2, 2017
Priority data
  • P2015-150344 (Jul 30, 2015) JP
Title PEPTIDE FRAGMENT FOR TREATING AUTOIMMUNE DISEASES meetings
Abstract Provided is a new means for effectively treating diseases including autoimmune diseases and the like. This peptide fragment has an amino acid sequence from position 46 to position 73, an amino acid sequence from position 160 to position 181, or an amino acid sequence from position 235 to position 261 in the amino acid sequence of carbonic anhydrase I (CAI), and includes 35 amino acid residues or less.
Outline of related art and contending technology BACKGROUND ART
Crohn's disease and ulcerative colitis including inflammatory bowel disease (IBD) is, characterized by failure of the immune system in the intestinal tract disease. And detailed a disease not yet clear, commensal bacteria, various microbial product, a natural immunity and acquired immunity and food excessive are considered to be one of the causes of the reaction.
Immunomodulation in microenvironment is, in order to maintain local homeostasis constantly need to be finely adjusted. This adjustment can be made, site specific (for example the digestive tract environment) and, to a microbe induced by chronic exposure of the considered. Dendritic cells, plays an important role in controlling this adjustment to be responsible for the. Dendritic cells, the most potent and effective antigen presenting cell, are responsible for the induction of the initial immune response. In addition, dendritic cells are important to the formation of immune tolerance to play a role. Of immune tolerance mechanism is not fully resolved, CD4 dendritic cells+ CD25- TCD4 cells+ CD25+ Foxp3+ T controllability by to differentiate into cells, inducing an immune tolerance at the periphery T cells has been reported (see non-patent document 1) are.
Patent Document 1 is, inflammatory bowel disease in the treatment of autoimmune diseases including carbonic anhydrase I (CAI) and the pulsed tolerogenic antigen-presenting cells can be utilized have been proposed.
Scope of claims (In Japanese)[請求項1]
炭酸脱水素酵素I(CAI)のアミノ酸配列の第46位~第73位のアミノ酸配列、第160位~第181位のアミノ酸配列、又は第235位~第261位のアミノ酸配列を含み、35アミノ酸残基以下であるアミノ酸配列から成るペプチド断片。
[請求項2]
炭酸脱水素酵素I(CAI)のアミノ酸配列の第46位~第73位のアミノ酸配列を含み、35アミノ酸残基以下であるアミノ酸配列から成る、請求項1に記載のペプチド断片。
[請求項3]
請求項1又は2に記載のペプチド断片を含有する自己免疫疾患の治療又は予防用医薬組成物
[請求項4]
経口投与用である、請求項3に記載の医薬組成物。
[請求項5]
請求項1又は2に記載のペプチド断片に特異的な寛容原性抗原提示細胞。
[請求項6]
制御性樹状細胞である、請求項5に記載の寛容原性抗原提示細胞。
[請求項7]
請求項5又は6に記載の寛容原性抗原提示細胞を含む自己免疫疾患の治療又は予防用医薬組成物。
[請求項8]
請求項1又は2に記載のペプチド断片をコードするポリヌクレオチド。
[請求項9]
請求項8に記載のポリヌクレオチドを含むベクター。
[請求項10]
請求項9に記載のベクターを組み込んだ形質転換体。
[請求項11]
請求項10に記載の形質転換体を含む自己免疫疾患の治療又は予防用医薬組成物。
  • Applicant
  • ※All designated countries except for US in the data before July 2012
  • NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY
  • Inventor
  • HIASA, Yoichi
  • YAGI, Sen
  • ABE, Masanori
  • IKEDA, Yoshioh
  • YAMASHITA, Masakatsu
IPC(International Patent Classification)
Specified countries National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JP KE KG KN KP KR KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL SM ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
Shikoku TLO is introducing the seeds of 4 inside 20 university and a technical college. Please ask to the following about the detailed contents of seeds. I am waiting for an inquiry.

PAGE TOP

close
close
close
close
close
close